Vas Narasimhan, Novartis CEO (Gian Ehrenzeller/Keystone via AP)

Up­dat­ed: No­var­tis trims pipeline by 10% as Vas Narasimhan places pre­mi­um on 'high-val­ue med­i­ci­nes'

No­var­tis is shed­ding around 10% of its pipeline as Vas Narasimhan’s cam­paign to turn it in­to a “pure-play” drug­mak­er goes full steam.

Fol­low­ing a “com­pre­hen­sive re­view of R&D projects” dur­ing the first quar­ter of 2023, the Swiss com­pa­ny said in its quar­ter­ly up­date that it’s de­cid­ed to dis­con­tin­ue or out-li­cense projects for con­sid­er­a­tions like strate­gic fit, as­set val­ue, com­mer­cial po­ten­tial and com­pet­i­tive land­scape.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.